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Abstract

The progression of regenerative medicine has advanced the treatment of multiple
illnesses and injuries throughout the years. A good example of the benefits of this research is the
work that has gone into volumetric muscle loss (VML), where more than 20% of the muscle is
loss. Skeletal muscle makes up 40% of the human body so a loss of that size greatly diminishes
the strength, the flexibility, physiology, and quality of life of the injured individual. For that
reason, various techniques are used to counteract the loss of structure and innate cellular
signaling in order to circumvent that from happening. Muscle flaps, for instance, are used to
avoid infection and to keep the remaining muscle from deteriorating more. However, this does
nothing to counteract the muscle mass loss or preserve the strength prior to injury. Scaffolds,
ECM gel, and minced muscle grafts can aid in provide a similar structure found in native muscle
as well as provide some cellular signaling that can encourage cell infiltration, reinforcing the
remaining supporting muscle. All of these treatment models utilize whole tissue which was then
placed back into the defect, either as a plug, minced, or having cellular components removed into
scaffolds. In this thesis, a reverse approach is explored wherein cellular components are used to
build up and create a scaffold that can be used to treat VMLs as well as how it compares to
previous repair strategies. Future directions goes into how this new scaffold research can be
applied to in the future to further our understanding of, not only VML recovery, but various other
injuries where fiber scaffolds would be a benefit.
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Chapter 1: Introduction

1. Skeletal Muscle
1.1 Anatomy and Physiology
The muscular system within the human body is involved in most aspects of its function,
from pumping the heart, to movement and digestion. The system can be divided into three
groups: cardiac, smooth, and skeletal muscle. All are essential to the body, but only skeletal
muscle under conscious control. This voluntary movement is a major part of our daily lives in
obvious ways, such as walking, and subtle ones, like regulating sound within the ear. Skeletal
muscle makes up 40-50% of total body mass, contains 50-75% of the body’s proteins, and
generates force in addition to producing high concentrations of energy [13, 58, 65]. Upon
contraction, the muscle is able to completely return to its relaxed state with no additional work
required, due to this energy storage [10, 37].
Skeletal muscle’s form is dictated by to its intended function. These forms are mainly
related to fiber orientation. Within all muscles, the fibers run aligned to one another. It is the
relationship between these fibers to their tendon that dictates the contraction pattern. For
example, pinnate muscles are flattened, with muscle fibers attached to the tendon at an angle.
The orientation of the fibers and tendon results in an angular contraction. Pinnate muscles
contain more fibers in a given volume and this increased cross-sectional area creates more force.
Parallel muscles have muscle fibers that run alongside each other. Parallel muscles can also be
broken into fusiform and non-fusiform, with fusiform muscle having a wide mid-belly and nonfusiform being uniform throughout. [36, 62]
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Single muscle fibers, or myofibers, within the muscle consist of myofibrils. Myofibrils
run longitudinally to one another in close proximity and are created from myoblast cells. These
embryonic cells begin the process of creating a myofibril by fusing together and forming a long
tendril. During this process, the individual nuclei of the myoblast is maintained and creates a
multinucleated structure. Multiple myofibrils are then packaged in sarcoplasm, nuclei migrates
to the periphery, and a myofiber is created. Transverse tubules connect the myofibrils, enabling
them to chemically communicate upon contraction occurs. [51, 59]
Myofibrils are composed of thick (myosin) and thin (actin) filaments. Thin filaments are
connected to one another through transverse actin, which creates a Z-line and marks the
boundary of a sarcomere. Thick filaments attach the myosin to the Z-line via titin filaments.
When titin is shortened, Z-lines move closer together and form a full overlap between the thick
and thin filaments. Relaxation causes Z-lines to move farther away from one another and the
myofibril returns. [9, 51]
Within myofibers, satellite cells run along its length, encased in basal lamina. Satellite
cells are essentially muscle stem cells and contain the ability to add to their parent muscle fiber
by differentiating into myoblasts or myogenic precursor cells when necessary. Due to this, small
rips and tears in the muscle are mended efficiently [36, 59]. Satellite cells lie in a quiescent state
until muscular injury occurs. Cells then become activated, migrate between myofibers and
muscles, and differentiate to repair the injury. Satellite cells expressing Pax7 are in their
quiescent or proliferating stage whereas an increase of MyoD relates to myogenic commitment
and differentiation [65]. Due to this signaling, a Pax7: MyoD ratio can be used to determine
whether or not repair is occurring. [9, 40, 53, 65]
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In addition to satellite cell healing, injury also begins an immune response. In healing,
there are two stages: inflammation and regeneration. Neutrophils initiate the start of the immune
response within the first 24 hours and activate the M1 macrophages. M1 macrophages are proinflammatory, causing mast cell degranulation, breaking down red blood cells, and hindering the
ability of blood to coagulate. This inflammation phase starts being resolved with the arrival of
regulatory T cells, which aid in transitioning to regeneration. They also regulate immune
response by coordinating interactions of immune cells within the muscle during the regeneration
phase. M2 macrophages are coupled with regulatory T cells and start the resolution of
inflammation by differentiating myogenic precursor cells, starting myogenesis. [36, 59]

1.2 Volumetric Muscle Loss
While we can use the aforementioned strategies to resolve smaller injuries in the muscle,
larger injuries are not resolved as easily. Volumetric muscle loss (VML) occurs when more than
20% of a muscle’s total volume is lost in a traumatic event. This loss of the muscle’s
regenerative cells and the extracellular matrix (ECM) overwhelms the self-healing process in a
way that leads to permanent disability. In a cohort of 450 retired service members, 39 were
discharged with a muscle-related disability and, of those, 92% had confirmed VMLs [8],
resulting in lifetime disability payment of $444,200 on average.
This disability is due to a prolonged inflammation phase during VML recovery. The
inflammation phase results in normal muscle fibers being replaced with fibrotic material,
resulting in scar tissue within the wound. Fibrotic material diminishes the muscle’s producible
force and can lead to atrophy. It also interferes with integration of regenerative structures that
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might aid in overcoming the loss of function, such as forming new vascular and neural
structures. [6, 8, 34, 48]
Currently, the most common treatment for volumetric muscle loss injuries in humans is
muscle flaps and limb bracing. Autogenic muscle flaps help to reduce complications and aids in
bone regeneration and increasing bone blood flow [12, 34, 47, 52] and bracing the limb can aid
in physical therapy afterwards [23, 34]. However, neither of these methods aid in preventing the
loss of muscle functionality that leads to permanent disability [15, 25]. No clinical method
available addresses the loss of structure and function following VML. [8, 11, 23]

2. Current Treatments
With this in mind, improving the functional capacity following a VML crucial. Tissue
regenerative approaches are being explored as a way to recover this functional loss through
medicine, rehabilitation, and implantation to aid in the healing process [15]. Effective treatments
have been grafting with specific structures found within normal muscle, such as nerve [39, 45]
and vascular structures [30, 32, 42, 64], as well as allografts of minced muscle, scaffolds from
de-celled whole tissues, and gel ECM deposits. The glaring question remains: what treatments
are most effective?
Meta-analyses done by Greising’s group [22] found multiple studies indicating that
treatment lead to an average improvement of 16% in functional capacity VML research
primarily explores treatment methods of acellular biomaterials, cells, growth factors, and
rehabilitation or a combination of the four. Improvement favored an acellular biomaterial with
cells, followed by the acellular biomaterial alone and biomaterials with growth factors. For
4

rehabilitation, Aurora et al [2] found voluntary wheel running improved torque (17%) and
muscle mass (13%), where as other groups found benefits within different rehabilitation
exercises, such as ladder climbing and treadmill running [46, 54]. Despite this and indication
that there was some force recovery in the early stages, the overall functional capacity was
worsened with rehabilitation [22, 48, 61]. This indicates that producing an effective regenerative
treatment is the best course of action when treating a VML.

2.1 Structure
As discussed previously, healthy skeletal muscle is characterized by the structural
alignment. Kim et al [30] attempted to address the importance of this alignment by taking
autografts of muscle and implanting them at varying orientations. The grafts were removed from
the tibialis anterior (TA), rotated 0o, 45o, and 90o, and sutured back into the defect. Following 8
week recovery, aligned autografts significantly improved the peak tetanic force and misaligned
grafts produced a significant increase of non-contractile tissue and fibrotic material. The aligned
autografts also presented genes promoting repair, such as MyoD and Pax7, in a significant
amount following two week repair. Compared forces produced at 2 weeks and that of 8 weeks
found that the aligned autograft had a significantly higher force recovery of ~60% between the
two time points whereas misaligned groups increased only by 20%. This indicates that the
alignment of the implanted treatment material in addition to cellular components in a VML are
important to its recovery.
Angiogenesis is another way to evaluate recovery following a traumatic injury.
Organization within the implanted material affects the ability of the graft to integrate with the
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host and remodels the vascular network [30]. Producing a vascular graft that is able to mimic a
healthy muscle creates a similar number of capillaries within the middle of the defect, as seen by
Yazdani et al [64]. In addition to this, treating VMLs with aligned scaffolds increases the
density of CD31 and isolectin within the wound, indicating that aligned scaffolds also directly
improve the micro-vascularization within the muscle and the perfusion of vascularization with
the defect as a whole, increasing the functional recovery [30, 33, 42].
Nerves throughout the tissue contribute to the contraction of the individual fibers,
resulting in the contraction of the muscle as a whole. In mice, VML results in the loss of 59% of
nerves running throughout the muscle, creating a loss of force [5]. One way to counteract this
loss is by implanting a neural regeneration material within a VML defect. Passipieri et al [45]
aided VML recovery by repairing peripheral nerves with polycaprolactone nerve conduit guides,
both with and without adipose stem cells (ASCs). The grafts were successful, especially
compared to non-repair models. After twelve weeks, the application of these polycaprolactone
conduits led VML muscle to produce more force than non-repair models. Conduits implanted
with ASCs were similar to autografts and avoided donor site morbidity. 40% of the maximum
torque produced by the TA was recovered using the ASC delivery via nerve conduits method,
indicating that peripheral repair of neural damage is beneficial to the recovery following VML.
[45] Additionally, Mintz et al [39] found that re-innervation patterns within the defected region
of a VML return to the normal after six months. This indicates that peripheral and defect site
innervation improves functional capacity following injury and is important to consider when
treating a VML.
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2.2 Cell Delivery
Maintaining a structure is important to the functional recovery of a VML, but does not
address the loss of cell-signaling within the defect site. Therefore, cell delivery could be a viable
treatment method to VML. Cells can be replaced back into the defect via implantation or
injection. Minced muscle allografts contain the same cellular material, such as vascular and
neural cells, and protein signals found within healthy muscle. Corona et al [4] tested the
efficiency of allografts and found that there is an improvement of about 55%. This was further
proven by other projects [1, 5, 24, 26, 60]. In an untreated murine VML injury, a loss of strength
(59%), muscle mass (33%), and fiber number (29%) throughout the muscle were found. With
minced muscle used as a tissue regenerative treatment, the amount of fibers within the muscle
improved by 34% [5]. Despite this aiding in contractile strength, there was no significant
improvement in strength or muscle weight noted in their study. Additionally, minced muscle
grafts at frequencies higher than 50Hz produced a significantly improved normalized isometric
torque compared to a VML with no repair, which correlates to de novo fiber production [4, 43].
When minced muscle allografts are not applicable, cells can also be delivered to the
injury site via injection. Kim et al [27] injected C2C12 myoblasts and human muscle progenitor
cells into a VML injury in order to improve cell survival and support reconstruction of the tissue.
They found that a single injection of the cells significantly increased the muscle thickness, but
multiple injections improved mass and vascularization. Additionally, multiple injections
increased oxygen diffusion within the defect and reduced fibrosis. [27] This indicates that
providing injury sites with muscle cells can reestablish signaling and combat some of the
detrimental effects seen following VML.
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2.3 Decellularized Scaffolds
VML injuries benefit from treatments that address the loss of structural and cellular
components. One way researchers looked to combine these two elements is with scaffolds.
Scaffold provide ECM structure within the defect and can be combined with cells to promote
regeneration. Moreover, decellularized scaffolds possess neural, vascular, and alignment
structures that have been found crucial in VML repair.
Wolf et al [63] decellularized canine whole quadriceps and hamstrings as well as porcine
small intestinal submucosa (SIS) in order to compare integration of the biological material within
a VML defect. Following decellularization, muscle scaffolds still retained associated
glycosaminoglycans and basement membrane proteins, with SIS scaffolds containing the greatest
amount. They also found a diminished amount of perivascular stem cells within the SIS-ECM
scaffolds, although SIS- and M-ECM had similar cell metabolic profiles. In vivo, there was not a
noticeable difference between implant sites, despite structure, composition, and host responses
differences in the early stages. Both scaffolds showed angiogenesis around them. [63]
Zhang et al [66] found that the perfusion method of decellularization kept important
components of the scaffolds, such as vascularization, neural channels, and the architecture,
intact. This decellularization method was aimed to reduce the amount of cellular debris
remaining within scaffolds without crosslinking or denaturing structural proteins or stripping the
scaffold of its ECM growth factors. The ultimate force this scaffold was able to produce was
comparable to native muscle scaffolds, even though there was a tensile stretch increase of 40%.
Researchers had previously linked the shrinkages of these scaffolds to in vivo performance.
Scaffold shrinkage increased the loss of coverage and dislodging the scaffold from placement.
This resulted in increased fibrosis occurring within the repair site, so minimizing the amount of
8

shrinkage of the implanted material is important to the efficiency of the scaffold. With this new
decellularization process, they found significantly reduced shrinkage after 8 weeks of recovery
compared to SIS-ECM scaffolds. Muscle fiber growth was found in residual endomysium of the
perfusion scaffolds, which is needed to maintain normal mechanical properties following
implantation. Furthermore, this profusion method promoted myogenesis and remodeling at the
repair site. [66]
Another scaffold that has been tested to treat VML was decellularized bladder tissue.
Corona et al [7] studied bladder acellular scaffold (BAM) as well as that same scaffold seeded
with muscle-derived cells prior to implantation (TEMR). Compared to no repair, BAM yielded a
26% functional improvement, with a significant increase in torque and a low rate of
inflammation. TEMR responders improved over BAM but produced a moderate amount of
inflammation. This study had both TEMR responders and non-responders; researchers found
that the potential difference between them was the quality of the TEMR constructs. Damaged
constructs might behave similarly to a whole tissue transplant [3], causing a change the immune
response within the defect, and is therefore susceptible to more inflammation that could have
lowered the functional recovery of the muscle. [3, 7]
Dziki et al [11] looked into 13 individuals suffering from VML. The patients were
treated with urinary bladder ECM biologic scaffolds and was evaluated on strength, flexability,
and muscle mass. The cohort was made up of ages 35.8 ± 10.2 years, where more than 20% of
muscle was lost (an average of 66.2%). In terms of strength, there was a significant increase in
force exerted by the treated limb of 37.3 ± 12.4% after 24 weeks of recovery. Various exercises
explored the range of motion patients were able to perform and found a large improvement when
individuals were treated with scaffolds. 12 of 13 showed a 20%+ improvement in performance in
9

the 10 to 12 weeks following the surgery. Six months following surgery, there was still a
marketed improvement, with some individuals having improvements anywhere between 324%
and 1,820% in tasks such as lifting chairs, hopping on a single leg, and single leg squats. Muscle
mass was also improved in response to treatment. [11]

2.4 Manufactured Scaffolds and Gels
The vast majority of the treatments have enhanced the abilities within the muscle as well
of the individual following VML treatment [6, 8, 11, 23]. However, a challenge of these
scaffolds is structure limitations and its ability to completely fill the defect following injury. A
way of counteracting this is to engineer new scaffolds. Manufactured scaffolds may open doors
into future projects and extend the application of care.
Lai et al [32] created a method of making collagen scaffolds by using collagen-Type1
from rat tail, a syringe, and a glass slide. They were able to control alignment: producing highly
aligned collagen fibers and randomly aligned collagen that had no obvious directionality in
alignment. The aligned collagen strips influenced endothelial cells; the cells were affected by
the orientation of the collagen strips and began growing in alignment with collagen. On
randomly aligned strips, the endothelial cells maintained a circular shape. These collagen strips
were originally created for vascular tissue engineering applications; however the ability of their
alignment made it an apt study within muscle as well. [32]
Nakayama et al [42] adjusted the above vascular graft structure to be more
accommodating to muscle by growing vascular and myoblast cells together. The implantation of
these scaffolds onto VML murine models was used to explore their proficiency in innervation
10

and the effect of exercise with treatment. They had previously compared capabilities of
nanofibrillar scaffolds and found that their aligned scaffolds were significantly stronger and
stiffer than the randomly-oriented scaffolds [41]. After implantation, perfused vascular and total
capillary density favored scaffolds. This improvement was further improved when voluntary
exercise was included. Scaffold-treated individuals also exhibited larger myofiber cross
sectional area and re-innervation was noticeable with mature neuromuscular junctions in
scaffold-treated animals. Neuromuscular junctions were found closer to the treatment site in
aligned scaffolds, with junctions found within 500μm from scaffold implant site. In all,
fabricated scaffolds can be manufactured with an alignment that is able to promote myogenesis,
angiogenesis and innervation within a VML, which is similar to the results seen in decellularized
scaffolds. [41, 42]
To ensure complete wound coverage, ECM gels could be beneficial. Matthias et al [38]
loaded muscle-derived stem cells onto fibrin microthreads, injected them into VMLs, and proved
they reduced fibrotic material deposited within the wound. Satellite cell production was
noticeable due to the increase expression of Pax7 following ECM gel injection as well. Page’s
group [44] took this approach and found that using models treated with gel alone were not
significantly different from the control groups in terms of fiber area and muscle area percentage,
unlike the gel with cells. All treatment groups using the gels were different from the native, with
significantly higher amount of centrally located nuclei and a significantly reduced fiber crosssectional area. [38, 44]
ECM gel structure and manufactured scaffolds are promising tissue engineering
techniques to come. ECM gels can lack structure depending on concentration and may produce
uniformed infiltration of cells. However, they are not limited in their implantation regions and
11

are able to completely fill the defect [16]. Manufactured ECM scaffolds allow for more structural
control and can be produced using natural materials such as collagen, but fabrication is variable
depending on the specific application [35]. Roberts et al [49] addressed some of these challenges
by means of sacrificial hollow fiber membranes (HFM). These membranes produced ECM fibers
from material secreted by the cells. The fibers are easily manipulated into aligned structures and
can support different cell types, such as astrocytes and skeletal muscle fibroblasts. Control over
both the structure and ECM production can expand the regions of implantation, which could
prove to be a new method of care in a VML. [49]

3. Objectives
The research presented here aims to provide evidence that cell-derived ECM fibers can
create a functional and effective scaffold to treat a VML, further expanding the available tissue
engineering strategies. We explore the hypothesis that ECM fiber-derived scaffolds are
comparable to decellularized skeletal muscle (DSM) scaffolds in terms of torque force, muscle
mass and morphology, and innate proteins found within the scaffold that promote cell-infiltration
while still maintaining the structure associated with skeletal muscle.
Scaffold investigations focused on treating VMLs has been limited to what we call a ‘topdown’ treatment: a whole muscle that has been decellularized in order to be placed into a defect.
Cells are able to infiltrate into DSM scaffolds and have been proven effective as a viable
treatment for a VML [14, 25, 62]. A ‘bottom-up’ scaffold takes cells found within whole muscle
and produces ECM structures from them, producing bulk multi-fiber scaffolds. We have seen
with previous studies that ECM itself is beneficial to the recovery of VMLs, so producing ECM
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from cells may produce more bio-complex ECM structures than what is seen in fabricated
scaffolds currently.
Our repair strategy is compared to an untreated VML. Decellularized skeletal muscle
scaffolds treated with minced muscle repair strategy (DSM+MM), which has previously
demonstrated its ability to improve the functional outcomes of VMLs, and is produced from the
same material of the intended implantation site. The structure preserved within the DSM
scaffolds allows for minced muscle to integrate better within the defect site, so we attempted to
create a similarly-structured scaffold so that the allograft of mince muscle can follow the same
reparative nature we have seen work previously.
Our approach follows this outline:


Produced ECM fibers using muscle-derived cells and probe their composition for
comparison to DSM.



Create bulk multi-fiber scaffolds and examine their structure, with a particular focus on
alignment.



Test the performance of ECM fiber scaffolds using a small animal VML injury model.
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Chapter 2: ECM Fiber Scaffolds as a Repair Strategy in Volumetric Muscle Loss Injuries

1. Introduction
Skeletal muscle composes approximately 40% of the body’s total weight and is a very
robust tissue able to maintain posture, generate force, and aid in movement of the body. In
addition to being a large benefit to the overall function of the body, it is also able to regenerate
following minor injuries, such as rips and tears, with little to no repercussions to the individual in
terms of physiology following injury. Despite its ability to heal completely when subjected to
minor damage, a problem arises when the muscle is harmed on a larger scale. Volumetric
muscle loss (VML) occurs when there is a >20% loss of muscle; this is most commonly found
from larger injuries such as combat, surgeries, sporting injuries, and car crashes. [10, 14, 35]
VML injuries overwhelm the healing process and encourage the integration of non-contractile
tissue, hindering the ability of the muscle fibers to contract, and therefore limiting the innate
muscles function, leading to chronic pain, disability, and cosmetic defects in conjunction with
these functional impairments [32]. Due to the complexity and detrimental nature of muscle loss,
efficient means of healing or improving the repair methods are needed.
When there is a loss of this size, repair options are available. Most commonly, muscle
flaps protect the damaged area and allow for an improvement of vascularization and preventing
infection [20]; however a call for a more robust strategy is needed to improve functionality and
morphology. One of the more promising techniques in research is decellularized scaffolds, which
provides a preservation of structure by removing cellular components but preserving the
extracellular matrix (ECM) of the tissue. This scaffold method has proven to improve strength
and muscle mass while improving functionality by forming new fiber bundles and reducing the
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deposit of non-contractile tissue [18, 37]. This study wanted to explore a way to engineer a new
scaffold while maintaining the structure and recovery benefits seen within decellularized tissue.
To do this, our lab explored a technique previously done by our lab: fabricated hollow
fiber membranes that are able to grow cells in a highly aligned manner. We believe that the
production of these fibers can be utilized for the production of scaffolds as we are able to
dissolve the membrane, decellularize and manipulate the remaining structures into a scaffold
[30], with a final ECM structure similar to what we see with decellularized skeletal muscle
scaffolds (DSM). Furthermore, engineering these ECM fibers allows for a reversal of the typical
construction of scaffolds. While scaffolds take a whole muscle and remove cellular components
to obtain the ECM structure within that can then be transplanted into a defect, these fibers allow
researchers have more control over the entire construction of the scaffold, from the cellular
components making up the fibers all the way to the alignment in every layer within the scaffold
in this ‘build-up’ type of method. The hypothesis explored within this study is that ECM fiberderived scaffolds are comparable to DSM scaffolds and a viable regenerative treatment for VML.

2. Materials and Methods
2.1 Hollow Fiber Membrane Fabrication
70g polysulfone pellets, 314mL of N-methyl-2-pyrrolidone (NMP), and a stir bar was
added into a borosilicate flask, closed with a stopper, and placed on a stir plate at a moderate
speed of rotation within a chemical hood for three days, or until homogenized. Alongside with
this “dope solution”, a “bore solution” was made up of 45mL NMP and 255mL of deionized
water. The dope solution was placed into a pressure vessel related to a spinneret’s polymer inlet
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and the bore solution was added to the bore inlet of the spinneret. The spinneret is suspended
8cm above a water bath and both solutions are released at 1 PSI. Large forceps were used to
manipulate the resulting fiber in the water bath and place it on a rotating wheel, set to a speed at
approximately two meters per minute, with adjustments being made so that the fiber bundle is
being collected on the wheel at the same speed of the solutions exiting the spinneret. Following
the creation of HFM, they were placed in a tub of deionized water for three days, exchanging the
water on each day. The resulting hollow fiber membranes (HFMs) were cut into ~7cm segments
and sterilized via autoclave at 121oC. The fabrication method has been reported previously [30].

2.2 ECM Fiber Scaffold Fabrication
To create ECM fiber scaffolds (Fig.1), HFMs were incubated in bovine plasma
fibronectin at 37oC for 1 hour at 1mg per 50mL PBS. Resulting HFMs were then placed into cell
culture flasks and seeded with rat musculoskeletal fibroblasts at 100,000 cells per fiber (Fig.1bc). Fibers were then incubated for three weeks at 37oC with 5% CO2 (Fig.1d). Media, containing
sterile-filtered 50mg/mL L-ascorbic acid and 150mg/mL L-ascorbic acid 2-phosphate combined
with DMEM/F-12 media, 5% L-glutamine, and 5% penicillin-streptomycin (pen-strep), was
exchanged every three days.
After three weeks of incubation, fibers were drained and placed into scintillation vials. A
cycle of three washes of n-methyl-2-pryllidone and three washes of distilled water dissolved the
polystyrene component of the fibers and the remaining extracellular matrix on the fibers was
used to prepare ECM fiber scaffolds (Fig.2a).
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Using an 8mm by 13mm silicone mold, fibers were manually aligned with forceps
(Fig.2d), parallel to the longer side of the mold, until opaque (Fig.2e), frozen at -80oC, and
lyophilized (Fig.2f). 1% sodium dodecyl sulfate in deionized water (SDS) was placed within the
molds of scaffolds and placed on a rocker plate, with gentile agitation, for 24 hours. Scaffolds
were washed thrice with sterile PSB and had DNAse/RNAse solution added and placed into 4oC
refrigerator overnight. DNAse/RNAse solution was created by adding 0.125mg DNAse I and
75µL Pure RNAse A stock solution to 5mL of a DNAse/RNAse buffer (308mg MgCl2, 56mg
CaCl2, and 1.54g of Tris HCl to 1L of deionized water). Scaffolds were rinsed another three
times with sterile PBS and then placed in a 10% Pen-Strep solution overnight. After three more
rinses in PBS, ECM fiber scaffolds were frozen in -80oC, and then were lyophilized, weighed,
and stored under sterile conditions at 4oC until implantation.

2.3 Decellularized Skeletal Muscle Scaffolds
Following euthanasia upon completion of a different study, TAs were collected from
Sprague Dawley rats were placed in 1% SDS on a stir plate with light agitation for 10 days,
exchanging SDS daily (Fig.3a). Samples are placed in DNAse solution (0.5mM CaCl2, 2.5mM
MgCl2, and 1kU/mL DNAse in 10mM Tris-HCL buffer) overnight and then moved into 1x penstrep. Following each preparation step, samples were thoroughly rinsed in PBS to remove all
remaining biological materials. Once all preparation steps are completed, the sample was
lyophilized (Fig.3c) and stored at -20oC until implantation.
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2.4 Proteomics
Both scaffold types had a sample (<5 mg) sent to UAMS in order to quantify protein
content. Purified proteins were reduced, alkylated, and digested using filter-aided sample
preparation [40] with sequencing grade modified porcine trypsin (Promega). Tryptic peptides
were then separated by reverse phase XSelect CSH C18 2.5 um resin (Waters) on an in-line 150
x 0.075 mm column using an UltiMate 3000 RSLCnano system (Thermo). Peptides were eluted
using a 60 min gradient from 98:2 to 65:35 buffer A:B ratio. Eluted peptides were ionized by
electrospray (2.2 kV) followed by mass spectrometric analysis on an Orbitrap Eclipse Tribrid
mass spectrometer (Thermo). MS data were acquired using the FTMS analyzer in profile mode
at a resolution of 120,000 over a range of 375 to 1200 m/z. Following HCD activation, MS/MS
data were acquired using the ion trap analyzer in centroid mode and normal mass range with a
normalized collision energy of 30%. Proteins were identified by database search using
MaxQuant (Max Planck Institute) with a parent ion tolerance of 3 ppm and a fragment ion
tolerance of 0.5 Da. Scaffold Q+S (Proteome Software) was used to verify MS/MS based
peptide and protein identifications. Protein identifications were accepted if they could be
established with less than 1.0% false discovery and contained at least 2 identified peptides.
Protein probabilities were assigned by the Protein Prophet algorithm [26].

2.5 Volumetric Muscle Loss Injury and Repair
Male Sprague Dawley rats, commercially purchased from Envigo (Indianapolis, IN),
underwent volumetric muscle loss (VML) surgeries at a weight between 325 and 350g.
Following University of Arkansas IACUC approved protocol (protocol #18055), VML defects
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were created using an 8mm biopsy punch inserted 3mm deep into the tibialis anterior (TA) and
were proportional to their surgical weight so as to maintain 20% muscle loss. Animals were
assigned into three types of repair groups: VML (no repair), decellularized skeletal muscle
scaffolds and minced muscle repair (DSM+MM), or ECM fiber scaffold and minced muscle
repair (ECM Scaffold), all n=8. DSM+MM followed previous studies and had decellularized
skeletal muscle scaffolds rolled in minced muscle before being placed into the defect, so that
DSM plug aligned with natural muscle. ECM fiber scaffold repairs placed one scaffold on the
bottom of the defect with 50% minced muscle laid over top. A second ECM fiber scaffold was
placed on top of the minced muscle. ECM fiber scaffolds were placed into defects so that the
fibers aligned with the natural muscle. The contralateral limb was left untreated to serve as a
control. All groups are administered 0.05mg/kg buprenorphine thrice over twelve-hour
increments (0hr, 12hr, 24hr time points) via subcutaneous injection and given the antiinflammatory medication (2mg of Rimadyl) every day for a week. Animals were housed
individually with unrestricted movement for an eight week recovery following surgery.

2.6 Electrophysiology
In order to acquire the peak of tetanic contractions of TA muscles, we followed
previously demonstrated studies by our group [18, 19, 27]. Following a distal tenotomies of the
extensor hallucis longus (EHL) and extensor digitorum longus (EDL) to ensure a proper force
measurement from an isolated TA muscle, lower limb paw was secured to the arm of a dualmode lever system from Aurora Scientific. The limb was secured such that the foot was 90o to
the shin, which was 90o to the femur. Percutaneous needle electrodes were placed within the
anterior compartment of the TA muscle and a physiological stimulator (Grass; S88) was used to
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stimulate the peroneal nerve. Tetanic contractions (150Hz, 0.1ms pulse width, 400ms train)
were taken in series to determine the optimal voltage from between 2 to 5 V. Allowing for a
1min rest periods between contractions, 3 consecutive contractions were taken and averaged for
the mean isometric torque values (N mm) and then normalized to weight (N mm/kg). The
untreated contralateral limb force was normalized (% uninjured, body weight, and TA mass) and
is presented in results.

2.7 Histology
Control, VML, and DSM and ECM fiber scaffold repaired TA muscles were all harvested
and cleared of fascia. Muscles were washed in PBS, dabbed dry, and weighed. Tissues were
flashed frozen in liquid nitrogen-chilled 2-methylbutane at -90oC and cross-sectioned via a Leica
BioSystems cryostat at 8µm, maintaining the temperature -25 to -20oC.
For staining, tissue was subjected to 0.1% 100X trition in order to permeabilize sections
and then rinsed in PBS. 4% goat serum and 0.05% sodium azide in PBS was used for blocking
for 2h at room temperature and followed by primary antibodies consisting of rabbit-anti-laminin
IgG, mouse-anti-collagen I IgG (both at 1:500, Sigma-Aldrich) at room temperature for 2h.
Slides were then washed in PBS and incubated in secondary antibodies (1:400, AlexaFluor, Life
Technologies) corresponding to previous primary for 1h. In order to visualize innervation and
vascularization, 100% acetone was used to permeabilize tissue for 5 minutes and rinsed with
PBS. Blocking was done the same as in previous stains, with an overnight primary incubation of
rabbit-anti-CD31 IgG (1:200, ABCam) and mouse-anti-MHC (1:250, Sigma-Aldrich) to stain for
capillaries and chicken-anti-NF200 IgY (1:250, EnCor) and laminin for innervation. Secondary
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incubations for both stains are the same as forementioned, with the exception of NF200, which
had a secondary stain of goat-anti-chicken IgY (1:500, Life Technologies). H&E was performed
following manufacturer’s guidelines (Sigma-Aldrich).

2.8 Image Analysis
For analysis of each immunofluorescence stain, each of the three treatment groups had
different representatives per group (n=5 per group), had three sections stained and imaged with a
total of at least three distinct regions within each individual section, for a total of at least nine
images per animal. Data was then averaged across the animal and imaged at 10x for both
collagen-I and laminin. To calculate the percent of non-contractile tissue, collagen-I staining
was used to calculate the area fluorescence against the area of the whole tissue image and then
was converted to a percentage using an automated MATLAB program. The cross-sectional area
of the muscle fibers was calculated using an automated free imaging software program (ImageJ,
NIH) that segmented out circular regions within the tissue, with an area of 200 to 5,000µm2,
wherein at least 150 individual muscle fibers were captured per image. Images was converted to
grayscale and then threshold in order to isolate borders of the fibers. Capillaries were imaged at
10x and manually counted using ImageJ in the same field of vision of ~150 muscle fibers per
image, similar to the process used for muscle fiber calculation. NF200 had whole muscle crosssectioned imaged and nerve bundles were manually counted.
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2.9 Statistical Analysis
Data is presented as mean + standard deviation unless otherwise stated and analyzed with
commercial statistical analysis software (JMP 13) with a standard level of significance of
p<0.05. ANOVA with post hoc Tukey’s test was used to compare peak tetanic force, percent of
non-contractile tissue, fiber cross-sectional area, and TA mass and growth rate.

3. Results
3.1 ECM Fiber Scaffold
After cells were incubated on the fibers and treated so that only the ECM components
remained, six individual fibers were isolated and measured both before and after lyophilization.
After removing the excess water, the wet weight was an average of 5.804 ± 3.04 mg and a dry
weight of 135 ± 106.2µg. Despite the difference in weight, all fibers were able to be handled.
The average of ECM fiber scaffolds was 6 ± 3.4mg after lyophilization, indicating 44+ fibers
were used in each scaffold.

3.2 Scaffold Alignment
Fig.2c depicts the underlying structure of a single fiber on a glass slide and, because of
how easily manipulatable the fibers are, we were allowed to control the alignment of the entire
scaffold before lyophilization. To determine alignment of the scaffolds, ECM fiber scaffolds
(n=5) were imaged and had individual fibers (n=9 per scaffold) digitally marked on ImageJ on
opposing ends and then had the slope from the coordinates calculated. The slope of these fibers
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was then compared to that found on the silicone edge of the mold. The degree of angle between
the silicone and the fiber was calculated by Eqn1.
m

fiber
θ = arctan (1+(m

−msilicone

)

silicone ∗mfiber )

Eqn1

The average degree of difference between the fibers and the mold was 10.99o ± 1.65.
Fig.2h shows that 80% of the fibers fall between 0 and 15 degrees of the scaffold and less than
5% greater than 30 degrees.

3.3 Proteomics
In addition to the alignment of the scaffold, we produced a direct comparison of proteins
between the ECM fiber scaffold and the scaffolds produced from decellularized muscle (Table
1.), which has been found to improve VML repair.

Table 1. Extracellular matrix proteins in DSM and ECM fiber scaffolds.
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Multiple proteins known to be found in association with extracellular matrix were found
in the sterilized (purified?) ECM fiber scaffolds, however only three primary ECM proteins
remained within the finished, decellularized TA scaffold: biglycan, collagen, and filamin.

3.4 Functional Outcomes
We found no significant difference between the mass of the ECM fiber scaffold-treated
muscles compared to the other treatment models, however uninjured muscles were significantly
larger than VML and DSM (Fig.5c). The force recovered after injury was not significantly
different between the three injury and repair models (Fig.5d) when compared to the
contralateral, uninjured hind limb. In Fig.5e, all muscles experienced a significant difference in
force normalized to body weight between the groups except the ECM fiber scaffold and
unrepaired muscles. While ECM fiber scaffold models were not significantly stronger from a
VML, the ECM fiber scaffolds were more similar to the uninjured (p= 0.0152) than the VML
(p=0.0021). Despite this, uninjured muscles, with an average of 5.44 ± 0.24 N mm/g, and VML
(4.97 ± 0.34 N mm/g) were both significantly stronger (p<0.005) than DSM+MM (3.18 ± 0.48 N
mm/g) (Fig.5f). ECM fiber scaffold repair was not significantly different from any other groups
in this instance, but was consistently more similar to the uninjured models in compared to mass,
percentage recovery, and peak torque compared to both body mass and TA mass.
Fiber area between groups was interesting. Fig.6b shows that, despite ECM fiber
scaffolds having a larger quantity of smaller fibers (<1,000 µm2), signifying the growth of
myofiber regeneration, DSM+MM had a larger formation of smaller fiber bundles of sizes from
1,000-2,499µm2, which implies that more fiber bundles have grown following an 8 week
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recovery. Uninjured muscle maintained a fairly equal amount of all the fibers of all sizes, with a
slightly larger amount of sizes from 2,500-3,999 µm2. Furthermore, there was a significant
difference between the average of the fiber areas in all groups except between uninjured and
DSM+MM, which had average values of 2400.58 ± 553.05 µm2 and 2300.09 ± 151.17 µm2,
respectively. In addition, the average size of the VML (1605.47 ± 156.63 µm2) and ECM
(1462.40 ± 95.43 µm2) fiber scaffold repairs (Fig.6c) myofiber bundles was also not significantly
different. Looking into the non-contractile tissue (%NCT), (Fig.6d) showed that there was
significant increase between the uninjured, VML, and biofiber scaffold repair, where p<0.05 for
between all groups. DSM+MM (10.65 ± 3.78 %) was the only group that did not have significant
differences between the uninjured and VML group, but was significantly different from the other
scaffold repair strategy (p<0.05).
We found a significant difference between the uninjured muscle and the three injured +
repair groups, but only ECM fibers produced more capillaries per fiber bundle than VML
(Fig.7b). Post-VML recovery tended to have an average of 1.74 ± 0.51 capillaries/fiber bunder,
but the uninjured normal was 3.08 ± 0.07, which is about 43.5% more. The DSM and ECM fiber
repair models did see some vascularization growth of 2.05 ± 0.26 and 2.36 ± 0.33 capillaries per
fiber bundle respectively, but ECM fiber scaffold repair showed 36% more capillaries than
VML. Additionally, we observed innervation, but no differences in quantities of the nerve
bundles following injury and repair was found. However, the size of fiber bundles seemed to be
different between the different injury models (Fig.8).
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4. Discussion
The purpose of this study was to ascertain if ECM fiber scaffolds with alignment tuned to
the direction of local muscle contraction would be an effective treatment for VML injuries. The
percentage of recovered force regenerated within the TA’s of the fiber scaffold models following
injury had an improvement over the both untreated and DSM treatments, despite there not being
a significant difference between them (Fig.4d). Even though there was slight force advantage
for these new scaffolds, responsive individuals were significantly stronger than VMLs. A
significant subset (n=6) of the whole sample (n=8) were considered responsive, improving the
percent recovery by 11.6%. 67% of the entire subset has a percent recovery higher than 75% and
a third of this same subset almost fully recovers, with a force recovery higher than 90%. One of
the possible contributors to the success in this subset could be size of the defect and the
relationship to the size of the ECM scaffold deposited into the wound site. As seen previously [1,
12, 29], the size of the defect can affect both the mass and torque, which could explain the results
we see within our new treatment method. The non-responsive animals had larger defect sizes
than the average of the cohort and smaller than the average of scaffolds, indicating that the ratio
of scaffold weight to defect is important to consider when using this recovery treatment. .
Although more research would need to be done in order to ascertain this claim, previous studies
have found that recovery is sensitive to the amount of ECM used to repair a defect, specifically
that dense-packing of ECM can result in a larger fibrotic mass instead of aiding in recovery [5,
15, 39]. Rats who received a large scaffold weight also produced more non-contractile tissue at
the wound site (~20% more than the average), leading researchers to infer that there is a desired
ratio of scaffold weight to defect size that would be more beneficiary to the recovery process that
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may lie somewhere between these two extremes. More research may also need to be focused into
a defect size that would benefit the most from these new scaffolds.
Myofiber sizes within the ECM fiber scaffolds were also smaller than the other repaired
group, comparable to the VML group, which might suggest newer fiber formation. A study
found that the cross-sectional area in regenerating myofibers is smaller, increasing the total
number of myofibers within the healing muscle [11], which we see in this study (Fig. 5). During
the remodeling phase of injured muscle, myofiber bundles rely on revascularization and
neuromuscular junction generation to reach maturity [2]. That said, our ECM fiber scaffold
repairs found more density of capillaries per fiber bundle than the other groups and numerous,
smaller nerve bundles were observed within this group as well (Fig.6). This leads researchers to
believe that the smaller myofiber bundles were simply new bundles growing and a longer
recovery period, such as a 12 week recovery, may yield larger, more mature fibers than what was
seen within this 8 week cohort. Future studies could compare an unaligned version of these ECM
fiber scaffolds to the aligned to see if we see either smaller myofibers or a reduced number of
myofibers, but within the tested aligned scaffolds, we did see an increased number of myofibers
of a smaller cross-section, in-line with what has been seen in previous studies. Additionally, we
may also need more information into the maturity of the surrounding nerve bundles and vascular
structures in order to ascertain the development of the necessary surrounding structures in order
to later aid in myofiber cross-sectional area growth.
To that end, we looked closer into the vascular and innervation components that play a
part in overall recovery of muscle function in this study. By staining with CD31, it was found
that with repair comes more capillaries, signaling that attempting to repair injured muscles
allows for new capillaries to form around myofiber bundles and therefore supplying necessary
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oxygen and nutrients to the new structures being produced. This vascularization is also optimized
by having an aligned structure, which encourages more proliferation than its randomly-oriented
scaffold counterparts [25]. Observationally, though, there was no noticeable change between the
groups in terms of ongoing nerve regeneration, even with the ECM fiber scaffolds have smaller
bundles. These smaller bundles may also have a higher threshold of stimulation, recruiting fewer
myofibers, and therefore have less of a response per unit compared to the larger bundles [34].
With this in mind, it might be prudent to research more about the stages of development of these
two factors in order learn more about the effect of the ECM fiber scaffold repair strategies, such
as looking further into VEGF and angiopoietins factors found within the wound sites as well as
looking into α-bungarotoxin and synaptophysin [9, 24, 33]. We saw improvement with
angiogenesis and there were differences in neurogenesis that we can further enhance those by
seeding fibers with cells. For instance, Schwann cell-seeding onto ECM fiber scaffolds could
also increase the likelihood of mature nerve bundles forming within a VML defect following
recovery, as these cells could guide the motor neuron regeneration [1, 17].
Along with torque recovery, another beneficiary aspect of these fibers is how highly
manipulative they are (Fig 1), which allowed for us to have 80% of the fibers within the
scaffolds between 0 and 150 of alignment to the scaffold mold. The alignment within the defect
of a VML injury affects the architectural cues [19, 23], which further affects force recovery and
the deposit of more fibrotic material; it is therefore necessary that the scaffolds implanted into
the defect are able to be aligned along with the natural muscle. Furthermore, our ECM fibers are
able to be highly aligned along the longitudinal axis [31], which was found to improve
vascularization and myofiber cross sectional area [24]. This highly aligned nature in conjunction
with how easily manipulative the fibers are allows for the control the alignment of the fibers

35

within the scaffolds, which can have the added advantage of matching the scaffold to the muscle.
While the ECM fiber scaffolds used within this study were implanted in the TA (a
circumpennate muscle), these new scaffolds are adjustable in alignment, in order to make them
suitable for a bipennate or multipennate muscles, like the rectus femoris or deltoid [21].
Matching the scaffolds to the morphological patterns within other muscle types encourages the
same pattern of myogenesis and opens the ECM fiber scaffolds to a wider range of use. For
instance, since 20% of the TA-specific scaffolds has fibers with >150 alignment, the 3D fiber
deposition technique [3, 28] can be utilized to ensure a stronger alignment that follows the
architectural cues of the natural muscle closer than can be accomplished manually (as seen here),
allowing for branching and more complex structures, seen within those different muscles. The
success of 3D printing these fibers could be aided by overcoming the low strength seen in the
individual fibers. ECM fiber bioreactors could be engineered in conjunction with media-soluble
factors, to improve the ECM production, increasing fiber strength. Mechanical stimuli on the
fibers as cells grow may also encourage ECM growth. All of these factors can not only aid in the
malleability of the fibers, but the likelihood that they will produce more structured scaffolds.
Additionally, we can adjust the fibers to create a heterogeneity of cellular composition to
further specify the recruitment of cell types within the defect. Following VML, capillary density
and the number of neuromuscular junctions is reduced [8, 24, 28, 36]. When these factors are
taken into account and adjusted in order to improve them during the treatment methods, more
mature neuromuscular junctions, larger myofiber bundles, vasculature density, and overall
muscle mass is improved [8, 24]. ECM fiber scaffold repair could benefit from having fibers
interwoven that have been grown up with neuron and vascular specific cells. Moreover, we are
able to seed these types of cells prior to implantation in order to encourage cell-to-cell signaling
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of this type. Future studies can be done in order to determine if these cell-type specific fibers are
producing similar benefits seen in previous studies [13, 22]. This can also be adjusted with
different muscle types, as stated previously, which would be a specificity benefit currently
lacking and broadening the use of ECM fiber scaffolds beyond only TA injuries.
Besides the vascular and nerve proteins previously mentioned, we also looked into the
individual proteins in the scaffolds themselves and compared those findings to ECM structures
expected within innate skeletal muscle [7] and found numerous overlaps (Table 1). The ECM
scaffolds were created using only rat skeletal muscle fibroblasts; it might be possible for there to
be remaining proteins if fibers were to be grown up with endothelial cells and lower motor
neurons [6, 16]. Proteomics can then be used to see if cell-specific proteins are retained in order
to be beneficiary to the infiltration of the structures needed, which may aid in the long-term
recovery of the ECM fiber scaffold recovery model. Using proteomics, we can further assess if
nerve fibers are new or mature and what critical proteins we would want to integrate into these
scaffolds in order to improve neurogenesis. The same could be explored within vascular fibers
to promote angiogenesis.
Producing enough ECM fibers for scaffold production was limited to the production
system creating the hollow polysulfone fibers as well as space availability of the fibers within the
cell culture flasks. Previously, our group had grown fibers inside of a petri dish by injecting the
cells within the center [31]. In order to assess the most productive method of cell growth, we
injected cells inside 50 fibers and outside of 50 that were then placed upright into a T25 cell
culture flask for 3 weeks. The ECM fibers produced afterwards were similar in ease of
manipulability length, durability, and production and proved to be a more streamlined and timeconserving effort. Production can be improved more with the use of a bioreactor to exchange
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media for higher volumes of fiber production, also ensuring that fiber production is uniform
throughout the entire growth process and allow for larger fibers of different sizes that could
increase the size of the ECM scaffolds available for larger injury models.

5. Conclusion
Scaffold repairs improve recovery following injury, which is further proven in the case of
ECM fiber scaffolds. The ability to control the alignment of these fibers with a large amount of
accuracy is highly desirable because that can be directly translated into creating scaffolds for
different types of injures in different regions of the body. Manufacturing these fibers can also
upscaling of the production to make hollow fiber membranes longer so as to produce larger
scaffolds in general. In addition, animals that responded to fiber scaffold treatment had nearly an
80% recovery of force when compared to the uninjured contralateral limb as well as being
overall larger in mass, producing more capillaries, and forming more new instances of myofiber
bundles following injury. Growing the fibers with different cell types may further improve the
benefits we’ve seen so far by producing more proteins attached to the decellularized scaffolds
following production, which can be further explored with further proteomic testing of these
different fiber types.
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Figures

Fig.1 ECM fiber fabrication process (a), starting with injecting cells on to fibers (b), allowing
cell attachment (c), and growing as a batch in T25 flasks for 3 weeks (d). DAPI-stained crosssection of a fiber before NMP treatment to remove polysulfone (d) as well as transverse fibers
without polysulfone (e) indicate cell attachment. Scale bar = 100μm
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Fig.2 ECM fiber scaffold fabrication showing decellularization of fibers (a) and representative
fiber length (b) as well as in microscale (c, scale bar = 500μm). Fibers were manually lain in a
silicone mold (d) until opaque (e). Lyophilized scaffolds (f) exhibited surface alignment (g, scale
bar = 1mm). Alignment of multiple scaffolds (n=5, 9 fibers/scaffold) was quantifiable as mean +
SD (h). ANOVA with post hoc Tukey’s test shown such that significantly different values are
indicated with different letters.
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Fig.3 Decellularized DSM scaffold in SDS solution (a) and prior to lyophilization (b). Scaffolds
were then lyophilized (c). DSM scaffold, stained with hematoxylin, where arrow signifies
direction of contraction (d). Scale bar = 100µm.
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Fig.4 Illustration of ECM scaffold repair strategy (a). After TA muscle is exposed (b), defect was
produced with an 8mm biopsy punch (c). For DSM scaffold repair, DSM scaffold was
implanted (d) and minced muscle was returned to defect (e). ECM scaffold was implanted deep
in defect (f), minced muscle was returned on top and the second ECM scaffold was implanted
superficially to the defect (g). Following VML, DSM repair, or ECM repair, fascia and skin was
then sutured closed (h, i, respectively).
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Fig.5 Gross morphology of all muscle groups (a), post tetanic measurements. In vivo isometric
tetanic torque waveform representatives (b, 150Hz, 400 msec train, 0.1 msec pulse width). TA
muscle weight (c) and relative (% uninjured) peak torque values were recorded (d), as well as
peak torque values normalized to body mass and TA mass (e, f, respectively), mean + SD.
ANOVA with post hoc Tukey’s test: *p<0.05, **p<0.01, ***p<0.001 for n=4-8/group.
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Fig.6 Representative images of uninjured, VML, DSM+MM repair, and ECM Fiber repair
strategies stained with H&E, laminin, and collagen I (a). Myofiber cross-sectional area
frequency distribution (b) and average cross-sectional fiber size, mean + SD (c). Non-contractile
tissue area fraction, mean + SD (d). ANOVA with post hoc Tukey’s test: *p<0.05, **p<0.01.
Presented as mean + SD. Scale bar = 100µm.
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Fig.7 Representative co-staining of CD31 and MHC showed vascular features (indicated with
arrows) around myofiber bundles (a). Capillaries per fiber calculated by total capillary /total
myofiber bundle, mean + SD (b). ANOVA with post hoc Tukey’s test: *p<0.05, **p<0.01. Scale
bar = 100µm.

Fig.8 Staining groups (uninjured, VML, DSM+MM, and ECM fiber scaffold repair) with NF200
and laminin. Bottom panel is magnification of inset. Scale bar = 100µm.
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Chapter 3: Conclusion and Perspectives

1. Future Directions
This study provided evidence that ECM fiber scaffolds improve the functional capacity of
a VML. Treatment increased muscle mass, peak tetanic force, and angiogenesis in the TA
compared to untreated muscle. However, some results indicate improvements can be made.
Myofiber cross-sectional area and non-contractile tissue was decreased following repair, which
could indicate remodeling was not complete or that the scaffold implant was not completely
integrated. An easy way to assess if this is true would be by extending the recovery time to 12
weeks. Many studies [11, 14, 19] find improvement in repair strategies with a longer recovery
time and this may be reflected in the ECM fiber scaffolds. Remolding would be fully complete
after this three month period and would be a more accurate reflection of how the scaffold effects
fiber size and non-contractile tissue. Additionally, the ECM fiber scaffold could be fully
degraded, resulting in less fibrotic material deposited in the muscle.
A two week study could also be illuminating by evaluating protein production following
our repair. In a shorter recovery, enzymes and proteins would still be actively remodeling the
muscle and can be indicative of proliferation within in the defect. An enzyme-linked
immunosorbent assay (ELISA) can be used to indicate angiogenesis, innervation, myogenesis,
and satellite cell production. ELISA has been used previously to quantify VEGF, HSP, MyoD,
and Pax7 expression [5, 8, 9, 24] and quantification of the ECM fiber scaffolds would indicate
how the muscle responds to repair.
The results seen within this study were only to evaluate ECM fiber scaffolds as a new
method of VML treatment. Due to initial results having shown promise, expanding ECM fiber
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production and methodology can further assess this. In this study, we only used one type of cell:
fibroblasts. However, different cell types are able to be successfully seeded onto hollow fiber
membranes [22]. As these fibers are the basis of this new scaffold, different cell types might
adjust the composition of the ECM secreted onto the fibers. For example, ECM secreted by
vascular cells may contain more angiogenic proteins than produced by fibroblasts or Schwann
cells [7, 15]. Adjusting this ECM composition might influence different cell proliferation and
attachment, improving vascularization and innervation following injury. Using the same
proteomic method from this study, we could then quantify proteins from different fibers grown
from different cell types to verify secreted ECM can be more cell-specific.
Cell-specific ECM fibers can then be used to create more complex scaffolds. Instead of
scaffolds made from fibroblast fibers only, we can place vascular and nerve fibers in the
scaffolds to better match the composition seen in normal muscle. This could then be tested for
increased angiogenesis and innervation within the defect. Depending on results, the cell-specific
fibers may make ECM fiber scaffolds more appropriate for repair. Furthermore, these scaffolds
can also be implanted with cells seeded onto the fibers. We’ve seen similar seeding processes
with cardiac [25] and pluripotent stem cell derived cells [10]. Seeded cells onto scaffolds further
aid in muscle regeneration, so ECM fiber scaffolds that have been seeded with cells could
improve remodeling and repair in a VML.
A limitation in this study is the fiber production. Currently, fibers are grown in small
batches in stagnant media. While we do add soluble chemicals promoting cellular ECM
secretion, it is unsure if media stagnation allows for all cells to have full access fresh media for
the entirety of cell culture. Improving the cell culture environment may cause more cell
proliferation and decrease the amount of time needed to create an ECM fiber. Bioreactors may
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be a solution to this problem while maintaining the same sterility and functionality [23]. The
flow of fresh media may encourage more ECM secretion and improve cell division, producing
fibers quicker than our current 3 week culture. Another benefit in using a bioreactor is extra
ECM secretion can result in stronger ECM fibers, decreasing the fragility during washing and
scaffold fabrication.
Another engineering strategy that could be beneficial to streamlining ECM fiber scaffold
production could be 3D printing scaffolds [3, 13]. Printing scaffolds from ECM fibers allows for
more control over the alignment within the middle of the scaffold, which was not evaluated here,
and could expand the form of the scaffolds. 3D printing can create angled scaffolds matching
the different muscle types and create scaffold of different sizes, better fitting the VML implant
site.

2. Treatment Challenges Remaining in VMLs
While ECM fiber scaffolds benefit VML recovery in terms of force, mass, and
vascularization, there still fibrous material deposited onto the surface of the muscle. Integration
of scaffolds with the surrounding muscle is persistent obstacle within muscle regeneration due to
the biodegradation of the scaffolds. Hydrogels integrate well in skeletal muscle due to their
biocompatibility and degradation properties, with instances of 50% degradation after 14 days
[21]. They promote myogenesis following injury and decrease the fibrotic area compared to
injured and treatments with autografts [16]. However, acellular scaffold have been primarily
pursued instead of hydrogels do to the alignment similarity to skeletal muscle when using
decellularized structures. They are able to produce aligned structures within the center of the
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defect, whereas hydrogels are still under investigation if they can produce the same mechanical
property results [6]. Combining the degradation of hydrogels with the structure and scalability in
acellular scaffolds would be the best combination; it would lead to integration of the myofibers
within the scaffolds while minimizing the fibrotic material deposited on the surface of the muscle
following recovery.
Another challenge would be the lack of understanding of innervation within the muscle
as repair occurs. The most common method of indicating innervation within a defect is using
electrophysiology. However, the tetanic force production does not look into immature nerves
within the defect at later weeks of recovery. Understanding how and when nerves structures are
being formed from a scaffold could affect the production methodology of scaffolds in order to
include proteins or structures that promote innervation.
Expanding our understanding of innervation could better inform the tetanic force values
seen within VML injury and repair. While we are able to see innervation within muscle
following injury, there is no distinction between immature and mature structures. Immature
nerve structures may not be contributing as much to the force, but could be indicative that active
innervation is occurring, leading to increased force later. Staining for mature motor neural
markers TuJ1 and ChAT [27] could be beneficial to address this. TuJ1 is both a central and
peripheral nervous system marker and ChAT is an enzyme linked to mature motor neurons.
Additionally, TuJ1 in conjunction with HB9 and ISLET1 can be linked to immature motor nerve
regions [4, 27]. ISLET is a transcription factor that appears in motor neuron development and
HB9 is highly linked with ISLET expression (more than 90% [4]). A combination of these two
immature markers could verify that the positive stain is linked to the actual development of
innervation within a defect.
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